These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
232 related articles for article (PubMed ID: 30707922)
61. Evaluation of immunogenicity and protective activity in BALB/c mice of the 25-kDa major outer-membrane protein of Brucella melitensis (Omp25) expressed in Escherichia coli. Bowden RA; Cloeckaert A; Zygmunt MS; Dubray G J Med Microbiol; 1998 Jan; 47(1):39-48. PubMed ID: 9449948 [TBL] [Abstract][Full Text] [Related]
62. Comparison between immune responses and resistance induced in BALB/c mice vaccinated with RB51 and Rev. 1 vaccines and challenged with Brucella melitensis bv. 3. Hamdy ME; El-Gibaly SM; Montasser AM Vet Microbiol; 2002 Aug; 88(1):85-94. PubMed ID: 12119140 [TBL] [Abstract][Full Text] [Related]
63. Characterization of outer membrane vesicles from Brucella melitensis and protection induced in mice. Avila-Calderón ED; Lopez-Merino A; Jain N; Peralta H; López-Villegas EO; Sriranganathan N; Boyle SM; Witonsky S; Contreras-Rodríguez A Clin Dev Immunol; 2012; 2012():352493. PubMed ID: 22242036 [TBL] [Abstract][Full Text] [Related]
64. A Brucella melitensis M5-90 wboA deletion strain is attenuated and enhances vaccine efficacy. Li ZQ; Shi JX; Fu WD; Zhang Y; Zhang J; Wang Z; Li TS; Chen CF; Guo F; Zhang H Mol Immunol; 2015 Aug; 66(2):276-83. PubMed ID: 25899866 [TBL] [Abstract][Full Text] [Related]
65. The 16MΔvjbR as an ideal live attenuated vaccine candidate for differentiation between Brucella vaccination and infection. Wang Y; Bai Y; Qu Q; Xu J; Chen Y; Zhong Z; Qiu Y; Wang T; Du X; Wang Z; Yu S; Fu S; Yuan J; Zhen Q; Yu Y; Chen Z; Huang L Vet Microbiol; 2011 Aug; 151(3-4):354-62. PubMed ID: 21530111 [TBL] [Abstract][Full Text] [Related]
66. B. melitensis rough strain B115 is protective against heterologous Brucella spp. infections. Adone R; Francia M; Pistoia C; Pesciaroli M; Pasquali P Vaccine; 2011 Mar; 29(14):2523-9. PubMed ID: 21300102 [TBL] [Abstract][Full Text] [Related]
67. Induction of protective immunity against brucellosis in mice by vaccination with a combination of naloxone, alum, and heat-killed Brucella melitensis 16 M. Motaharinia Y; Rezaee MA; Rashidi A; Jalili A; Rezaie MJ; Shapouri R; Hossieni W; Rahmani MR J Microbiol Immunol Infect; 2013 Aug; 46(4):253-8. PubMed ID: 22727892 [TBL] [Abstract][Full Text] [Related]
68. Crystalline and Amorphous Preparation of Aluminum Hydroxide Nanoparticles Enhances Protective Antigen Domain 4 Specific Immunogenicity and Provides Protection Against Anthrax. Gogoi H; Mani R; Aggarwal S; Malik A; Munde M; Bhatnagar R Int J Nanomedicine; 2020; 15():239-252. PubMed ID: 32021177 [TBL] [Abstract][Full Text] [Related]
69. A new candidate vaccine for human brucellosis based on influenza viral vectors: a preliminary investigation for the development of an immunization schedule in a guinea pig model. Bugybayeva D; Kydyrbayev Z; Zinina N; Assanzhanova N; Yespembetov B; Kozhamkulov Y; Zakarya K; Ryskeldinova S; Tabynov K Infect Dis Poverty; 2021 Feb; 10(1):13. PubMed ID: 33593447 [TBL] [Abstract][Full Text] [Related]
70. Multi-Epitope Vaccine Candidates Associated with Mannosylated Chitosan and LPS Conjugated Chitosan Nanoparticles Against Brucella Infection. Sadeghi Z; Fasihi-Ramandi M; Davoudi Z; Bouzari S J Pharm Sci; 2023 Apr; 112(4):991-999. PubMed ID: 36623693 [TBL] [Abstract][Full Text] [Related]
72. Protection of BALB/c mice against Brucella melitensis 16 M infection induced by vaccination with live Escherchia coli expression Brucella P39 protein. Al-Mariri A Vaccine; 2010 Feb; 28(7):1766-70. PubMed ID: 20036752 [TBL] [Abstract][Full Text] [Related]
73. Protection of BALB/c mice against homologous and heterologous species of Brucella by rough strain vaccines derived from Brucella melitensis and Brucella suis biovar 4. Winter AJ; Schurig GG; Boyle SM; Sriranganathan N; Bevins JS; Enright FM; Elzer PH; Kopec JD Am J Vet Res; 1996 May; 57(5):677-83. PubMed ID: 8723881 [TBL] [Abstract][Full Text] [Related]
74. Construction of an expression plasmid (vector) encoding Brucella melitensis outer membrane protein, a candidate for DNA vaccine. Vahedi F; Ghorbani E; Falsafi T Rep Biochem Mol Biol; 2013 Apr; 1(2):82-6. PubMed ID: 26989713 [TBL] [Abstract][Full Text] [Related]
75. Immunogenicity of major cell surface protein(s) of Brucella melitensis Rev 1. Mahajan NK; Kulshreshtha RC; Malik G; Dahiya JP Vet Res Commun; 2005 Apr; 29(3):189-99. PubMed ID: 15736854 [TBL] [Abstract][Full Text] [Related]
76. Evaluation of Brucella melitensis B115 as rough-phenotype vaccine against B. melitensis and B. ovis infections. Adone R; Francia M; Ciuchini F Vaccine; 2008 Sep; 26(38):4913-7. PubMed ID: 18675869 [TBL] [Abstract][Full Text] [Related]
77. Brucella lumazine synthase elicits a mixed Th1-Th2 immune response and reduces infection in mice challenged with Brucella abortus 544 independently of the adjuvant formulation used. Velikovsky CA; Goldbaum FA; Cassataro J; Estein S; Bowden RA; Bruno L; Fossati CA; Giambartolomei GH Infect Immun; 2003 Oct; 71(10):5750-5. PubMed ID: 14500496 [TBL] [Abstract][Full Text] [Related]
78. The identification of two protective DNA vaccines from a panel of five plasmid constructs encoding Brucella melitensis 16M genes. Commander NJ; Spencer SA; Wren BW; MacMillan AP Vaccine; 2007 Jan; 25(1):43-54. PubMed ID: 17049676 [TBL] [Abstract][Full Text] [Related]